USPTO Cancer Moonshot Challenge, 61196-61198 [2016-21349]

Download as PDF mstockstill on DSK3G9T082PROD with NOTICES 61196 Federal Register / Vol. 81, No. 172 / Tuesday, September 6, 2016 / Notices utility or plant application filed under 35 U.S.C. 111(a) within the duration of the pilot program; (3) the nonprovisional application must directly claim the benefit under 35 U.S.C. 119(e) and 37 CFR 1.78 of a prior provisional application filed within the previous 12 months, and the specific reference to the provisional application must be in an application data sheet under 37 CFR 1.76 (see 37 CFR 1.78(a)(3)); and (4) the applicant must not have filed a nonpublication request. As required for all nonprovisional applications, the applicant must satisfy filing date requirements and publication requirements. If the application submitted on filing does not meet the requirements for publication, or if the application is filed without any claims, the Office of Patent Application Processing will issue an appropriate notice setting a two-month (extendable) time period within which to respond. The Extended Missing Parts Pilot Program does not change the two-month time period set forth in any such notice. In accordance with 35 U.S.C. 122(b), the USPTO will publish the application promptly after the expiration of 18 months from the earliest filing date for which benefit is sought. If the applicant satisfies the requirements (discussed above) on filing of the nonprovisional application and the application is in condition for publication, the USPTO will send the applicant a Notice to File Missing Parts of Nonprovisional Application that sets a 12-month (non-extendable) time period to submit the search fee, the examination fee, any excess claims fees (under 37 CFR 1.16(h)-(j)), and the surcharge under 37 CFR 1.16(f) (for the late submission of the search fee and examination fee). If an applicant files a timely reply to the Notice to File Missing Parts within the 12-month time period and the nonprovisional application is completed, the nonprovisional application will be placed in the examination queue based on the actual filing date of the nonprovisional application. For additional discussion, see Pilot Program for Extended Time Period To Reply to a Notice to File Missing Parts of Nonprovisional Application, 75 FR 76401 (Dec. 8, 2010), 1362 Off. Gaz. Pat. Office 44 (Jan. 4, 2011), and Extension of the Extended Missing Parts Pilot Program, 80 FR 80325 (Dec. 24, 2015), 1422 Off. Gaz. Pat. Office 192 (Jan. 19, 2016). II. Request for Public Comments The USPTO is requesting written public comments on whether the Extended Missing Parts Pilot Program VerDate Sep<11>2014 17:04 Sep 02, 2016 Jkt 238001 should be made permanent. The USPTO seeks input from the public on the following: 1. Have you participated in the Extended Missing Parts Pilot Program? If so, please discuss what aspects of the program you think are beneficial and what aspects are not. 2. Please discuss why an applicant would be discouraged from participating in the Extended Missing Parts Pilot Program. 3. Do you think the USPTO should make the Extended Missing Parts Pilot Program permanent? Why or why not? 4. Please provide any other input that you would like the USPTO to consider in determining whether the Extended Missing Parts Pilot Program should be made permanent. Dated: August 29, 2016. Russell Slifer, Deputy Under Secretary of Commerce for Intellectual Property and Deputy Director of the United States Patent and Trademark Office. [FR Doc. 2016–21306 Filed 9–2–16; 8:45 am] BILLING CODE 3510–16–P DEPARTMENT OF COMMERCE Patent and Trademark Office [Docket No. PTO–C–2016–0032] USPTO Cancer Moonshot Challenge United States Patent and Trademark Office, Commerce. ACTION: Notice. AGENCY: The United States Patent and Trademark Office (USPTO) publishes this notice to announce the Cancer Moonshot Challenge, which was launched on August 22, 2016, to enlist the public’s help to leverage the USPTO’s intellectual property data, often an early indicator of meaningful research and development, and combine it with other economic and funding data. This challenge supports the goals and objectives of the National Cancer Moonshot, a Presidential initiative to speed up cancer advances, make more therapies available to more patients, and improve the ability to prevent cancer and detect it at an early stage. This notice provides the public with information on participation and application requirements for the challenge, including the judging criteria, submission requirements, and rules of eligibility. SUMMARY: Challenge Deadline: The deadline for submissions is September 12, 2016, 5:00 p.m. Eastern Standard Time (EST). DATES: PO 00000 Frm 00016 Fmt 4703 Sfmt 4703 All individuals or entities who wish to participate in the challenge must register and submit their entry through www.challenge.gov. FOR FURTHER INFORMATION CONTACT: For further information, please contact Thomas A. Beach, Office of the Under Secretary and Director, at 571–272– 8600. SUPPLEMENTARY INFORMATION: ADDRESSES: I. About the Challenge Background Cancer is undoubtedly a disease that touches all our lives. Ending cancer as we know it requires the formation of new alliances. As President Obama noted, getting this done isn’t just going to take the best and brightest across the medical, research, and data communities—but millions of Americans owning a stake of it. By harnessing the power of patent data and accelerating the process for protecting the intellectual property that leads to cancer immunotherapy breakthroughs, the USPTO is standing up and doing its part to help bring potentially life-saving treatments to patients, faster. The Challenge With data released through the USPTO Developer Hub, users are building rich visualizations of intellectual property data, an early indicator of meaningful innovation and research and development (R&D), and combining this data with other state or agency data, such as census and bureau of labor statistics, and/or economic and financial data. These types of visualizations demonstrate the power of telling complex stories that lead to impactful insights and ask why the data matters. Similarly, we challenge you to create and illuminate new trend lines and interactive mappings of innovation with visualizations for all types of cancer treatments and diagnostics by combining our data with other unique data. Be sure to list the sources of your data sets (i.e., orange book data from the FDA), tools, and assumptions used to form your conclusion and visualizations. Imagine your data visualizations will be the foundation to empower the Federal Government—as well as the medical, research, and data communities—to make more precise funding and policy decisions based on the commercialization lifecycle of the most promising treatments, while maximizing U.S. competitiveness in cancer investments. Using analytic tools, processes, and other interoperable data sets, we are challenging you to develop interactive visualizations and stories that can help E:\FR\FM\06SEN1.SGM 06SEN1 Federal Register / Vol. 81, No. 172 / Tuesday, September 6, 2016 / Notices reveal new insights to guide public policy and research to achieve the goal of doubling the rate of progress toward a cure. For example, you could address questions such as: Trending: • What new insights can be revealed by correlating R&D spending/funding to breakthrough technologies? How would you define or cluster the broad spectrum of cancer treatments, therapies, and/or diagnostics? • What would trace studies of commercially successful treatments from patent to product tell us? What data insights can be gleaned from understanding the time it takes bring patents to patients? • What are the peaks and valleys in the landscape of cancer treatment technologies? Policy: • If you were the Director of NIH or another agency, given what you have learned from this patent data and your research, how would you prioritize your cancer research budget? (The National Cancer Institute’s FY2014 budget was $4.932 billion.) • Based on cluster mapping of cancer treatments, therapies, and/or diagnostics, what policy would you put in place to promote certain technologies? For example, would you promote treatment to make cancer a livable disease verses curing it? • Is there any measurable relationship between patent data, clinical trial data, and time to it takes for the technology to be in the hands of the patient? If so, how (and with what catalyst for innovation and policy changes) would you advise the VPOTUS for the Cancer Moonshot? Moonshot can join today by visiting www.whitehouse.gov/CancerMoonshot. Resources III. How To Enter The USTPO has released a curated data set consisting of 269,353 patent documents (published patent applications and granted patents) spanning the 1976 to 2016 period. This data and associated documentation explaining our methodology can be found on the USPTO Developer Hub. By September 12, 2016, 5:00 p.m. Eastern Standard Time, submit the following items through www.challenge.gov: • A story (maximum 1,000 words). Written in English, tell the story of your visualization and walk users through how to use your visualization. The document must describe how your visualization provides meaningful insight, including potential actions and/ or discoveries. • Access to and testing instructions for your submission. This can be appended to your visualization description and does not count toward the 1,000 word maximum. • Link to the submission. We will not accept any submission without a link. Prizes mstockstill on DSK3G9T082PROD with NOTICES First Place: $5,000.00 Second Place: $3,000.00 Third Place: $2,000.00 More Information About the Cancer Moonshot Initiative As the President’s Cancer Moonshot Initiative looks to build public-private partnerships with industry, governments, health systems, nonprofits, philanthropy, research institutes, patients, and academia, those interested in advancing the Cancer VerDate Sep<11>2014 17:04 Sep 02, 2016 Jkt 238001 II. Judging Criteria • Creativity & Innovation (20%) Æ Uniqueness and innovation in approach to revealing new insights to guide public policy and research. Æ Concept should be original, fill a gap, or answer a question in a manner that is not already available. • Evidence Base & Effectiveness (20%) Æ Provide meaningful insight, including potential actions and discoveries, using patent-related data to better inform funding and policy decisions or uncover insights into the cancer R&D process. Æ How did you arrive at and validate your story? Did you include additional complimentary datasets to help solidify your story? What additional knowledge sources did you use? • Value to Public (20%) Æ Concept should add value to the medical, research, or data communities and policymakers, allowing them to make more informed funding and policy decisions based on the patterns and trends of innovation in cancer diagnosis and treatment. • Usability (20%) Æ The design elements should attract, engage, and influence actions from the public and policymakers. • Functional Product (20%) Æ The visualization should have demonstrable functionality as described in project description. IV. Rules To be eligible to win a prize under this challenge, an individual or entity: PO 00000 Frm 00017 Fmt 4703 Sfmt 4703 61197 (1) Shall have registered to participate in the competition under the rules promulgated by the USPTO. (2) Shall have complied with all the requirements under this section. (3) In the case of a private entity, shall be incorporated in and maintain a primary place of business in the United States; in the case of an individual, whether participating singly or in a group, shall be a citizen or permanent resident of the United States. (4) Shall not be a federal entity or federal employee acting within the scope of their employment. (5) Shall not be a USPTO employee working on their applications or submissions during assigned duty hours. (6) In the case of a federal grantee, shall not use federal funds to develop applications unless consistent with the purpose of their grant award. (7) In the case of a federal contractor, shall not use federal funds from a contract to develop applications or to fund efforts in support of a challenge submission. An individual or entity shall not be deemed ineligible because the individual or entity used federal facilities or consulted with federal employees during a competition if the facilities and employees are made equitably available to all individuals and entities participating in the competition. Entrants must agree to assume any and all risks and waive claims against the Federal Government and its related entities, except in the case of willful misconduct, for any injury, death, damage, or loss of property, revenue, or profits, whether direct, indirect, or consequential, arising from their participation in this prize contest, whether the injury, death, damage, or loss arises through negligence or otherwise. Entrants must also agree to indemnify the Federal Government against thirdparty claims for damages arising from or related to competition activities. By entering into this competition, entrants represent that the they possess liability insurance or are otherwise financially responsible for: (1) Claims by a third party for death, bodily injury, or property damage, or loss resulting from an activity carried out in connection with participation in the competition, with the Federal Government named as an additional insured under the Entrant’s insurance policy, if any; and (2) claims by the Federal Government for damage or loss to government property resulting from such an activity. E:\FR\FM\06SEN1.SGM 06SEN1 61198 Federal Register / Vol. 81, No. 172 / Tuesday, September 6, 2016 / Notices By submitting an entry to this competition you represent and warrant that your submission: • Is your own work and not copied (if we have reason to believe that your submission is not your own work then we may not consider it); • does not contain any third party intellectual property rights and/or content that you do not have permission to use; and • is not obscene, defamatory, or in breach of any applicable legislation or regulations. The USPTO reserves the right to cancel, suspend, and/or modify the challenge, or any part of it, for any reason, at the USPTO’s sole discretion. Submission Requirements • Your submission must use at least the cancer research dataset provided by the USPTO. • Your submission must be relevant to a U.S. audience and must be in the English language only. • You are responsible for the cost and expense (if any) of sending your submission to us and, if your submission is selected, either attending an awards event demo at the USPTO on September 26, 2016, in person or submitting a video of your presentation to be shared at the event. • Only one project submission is permitted per person or group. In the event of a dispute over the identity of an entrant, the submission will be deemed submitted by the authorized account holder of the email address submitted during the registration process. Submissions that do not adhere to the requirements listed above will be automatically disqualified. mstockstill on DSK3G9T082PROD with NOTICES Intellectual Property 17:04 Sep 02, 2016 Dated: August 31, 2016. Michelle K. Lee, Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office. [FR Doc. 2016–21349 Filed 9–2–16; 8:45 am] BILLING CODE 3510–16–P CORPORATION FOR NATIONAL AND COMMUNITY SERVICE Information Collection; Submission for OMB Review, Comment Request Corporation for National and Community Service. ACTION: Notice. AGENCY: The Corporation for National and Community Service (CNCS) has submitted a public information collection request (ICR) entitled Senior Corps Project Progress Report (PPR)— OMB Control Number 3045–0033 for review and approval in accordance with the Paperwork Reduction Act of 1995. Copies of this ICR, with applicable supporting documentation, may be obtained by calling the Corporation for National and Community Service, Jill Sears, at 202–606–7577 or email to jsears@cns.gov. Individuals who use a telecommunications device for the deaf (TTY–TDD) may call 1–800–833–3722 between 8:00 a.m. and 8:00 p.m. Eastern Time, Monday through Friday. DATES: Comments may be submitted, identified by the title of the information collection activity, within October 6, 2016. SUMMARY: Comments may be submitted, identified by the title of the information collection activity, to the Office of Information and Regulatory Affairs, Attn: Ms. Sharon Mar, OMB Desk Officer for the Corporation for National and Community Service, by any of the following two methods within 30 days from the date of publication in the Federal Register: (1) By fax to: 202–395–6974, Attention: Ms. Sharon Mar, OMB Desk Officer for the Corporation for National and Community Service; or (2) By email to: smar@omb.eop.gov. SUPPLEMENTARY INFORMATION: The OMB is particularly interested in comments which: • Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of CNCS, including whether ADDRESSES: Ownership of intellectual property is determined by the following: • Each entrant retains title and full ownership in and to their submission. Entrants expressly reserve all intellectual property rights not expressly granted under the challenge agreement. • By participating in the challenge, each entrant hereby irrevocably grants to sponsor and administrator a limited, non-exclusive, royalty-free, worldwide license and right to reproduce, publicly perform, publicly display, and use the submission to the extent necessary to administer the challenge, and to publicly perform and publicly display the submission, including, without limitation, for advertising and promotional purposes relating to the challenge. VerDate Sep<11>2014 • All entrants are encouraged to open source their code to the extent possible as a continuing contribution to cancer research. Jkt 238001 PO 00000 Frm 00018 Fmt 4703 Sfmt 9990 the information will have practical utility; • Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; • Propose ways to enhance the quality, utility, and clarity of the information to be collected; and • Propose ways to minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology. Comments A 60-day Notice requesting public comment was published in the Federal Register on 06/10/2016 at 81 FR 37582. This comment period ended August 9, 2016. No public comments were received from this Notice. Description: The Senior Corps PPR has two components: (1) Narratives and work plans, and (2) the Progress Report Supplement (PRS), which is an annual survey of volunteer demographics and grantee characteristics. Type of Review: Renewal. Agency: Corporation for National and Community Service. Title: Senior Corps Project Progress Report. OMB Number: 3045–0033. Agency Number: None. Affected Public: Sponsors of Senior Corps grants. Total Respondents: 1,250. Frequency: Work plans and narratives: Semi-Annual. Progress Report Supplement: Annual. Average Time per Response: Progress Report and Supplement: Twelve hours. Estimated Total Burden Hours: 15,000 hours. Total Burden Cost (capital/startup): None. Total Burden Cost (operating/ maintenance): None. Authority: Pub. L. 104–13, (44 U.S.C. Chapter 35) Dated: August 30, 2016. Mikel Herrington, Director, Senior Corps. [FR Doc. 2016–21327 Filed 9–2–16; 8:45 am] BILLING CODE 6050–28–P E:\FR\FM\06SEN1.SGM 06SEN1

Agencies

[Federal Register Volume 81, Number 172 (Tuesday, September 6, 2016)]
[Notices]
[Pages 61196-61198]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-21349]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Patent and Trademark Office

[Docket No. PTO-C-2016-0032]


USPTO Cancer Moonshot Challenge

AGENCY: United States Patent and Trademark Office, Commerce.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The United States Patent and Trademark Office (USPTO) 
publishes this notice to announce the Cancer Moonshot Challenge, which 
was launched on August 22, 2016, to enlist the public's help to 
leverage the USPTO's intellectual property data, often an early 
indicator of meaningful research and development, and combine it with 
other economic and funding data. This challenge supports the goals and 
objectives of the National Cancer Moonshot, a Presidential initiative 
to speed up cancer advances, make more therapies available to more 
patients, and improve the ability to prevent cancer and detect it at an 
early stage. This notice provides the public with information on 
participation and application requirements for the challenge, including 
the judging criteria, submission requirements, and rules of 
eligibility.

DATES: Challenge Deadline: The deadline for submissions is September 
12, 2016, 5:00 p.m. Eastern Standard Time (EST).

ADDRESSES: All individuals or entities who wish to participate in the 
challenge must register and submit their entry through 
www.challenge.gov.

FOR FURTHER INFORMATION CONTACT: For further information, please 
contact Thomas A. Beach, Office of the Under Secretary and Director, at 
571-272-8600.

SUPPLEMENTARY INFORMATION: 

I. About the Challenge

Background

    Cancer is undoubtedly a disease that touches all our lives. Ending 
cancer as we know it requires the formation of new alliances. As 
President Obama noted, getting this done isn't just going to take the 
best and brightest across the medical, research, and data communities--
but millions of Americans owning a stake of it. By harnessing the power 
of patent data and accelerating the process for protecting the 
intellectual property that leads to cancer immunotherapy breakthroughs, 
the USPTO is standing up and doing its part to help bring potentially 
life-saving treatments to patients, faster.

The Challenge

    With data released through the USPTO Developer Hub, users are 
building rich visualizations of intellectual property data, an early 
indicator of meaningful innovation and research and development (R&D), 
and combining this data with other state or agency data, such as census 
and bureau of labor statistics, and/or economic and financial data. 
These types of visualizations demonstrate the power of telling complex 
stories that lead to impactful insights and ask why the data matters. 
Similarly, we challenge you to create and illuminate new trend lines 
and interactive mappings of innovation with visualizations for all 
types of cancer treatments and diagnostics by combining our data with 
other unique data. Be sure to list the sources of your data sets (i.e., 
orange book data from the FDA), tools, and assumptions used to form 
your conclusion and visualizations. Imagine your data visualizations 
will be the foundation to empower the Federal Government--as well as 
the medical, research, and data communities--to make more precise 
funding and policy decisions based on the commercialization lifecycle 
of the most promising treatments, while maximizing U.S. competitiveness 
in cancer investments.
    Using analytic tools, processes, and other interoperable data sets, 
we are challenging you to develop interactive visualizations and 
stories that can help

[[Page 61197]]

reveal new insights to guide public policy and research to achieve the 
goal of doubling the rate of progress toward a cure. For example, you 
could address questions such as:
    Trending:
     What new insights can be revealed by correlating R&D 
spending/funding to breakthrough technologies? How would you define or 
cluster the broad spectrum of cancer treatments, therapies, and/or 
diagnostics?
     What would trace studies of commercially successful 
treatments from patent to product tell us? What data insights can be 
gleaned from understanding the time it takes bring patents to patients?
     What are the peaks and valleys in the landscape of cancer 
treatment technologies?
    Policy:
     If you were the Director of NIH or another agency, given 
what you have learned from this patent data and your research, how 
would you prioritize your cancer research budget? (The National Cancer 
Institute's FY2014 budget was $4.932 billion.)
     Based on cluster mapping of cancer treatments, therapies, 
and/or diagnostics, what policy would you put in place to promote 
certain technologies? For example, would you promote treatment to make 
cancer a livable disease verses curing it?
     Is there any measurable relationship between patent data, 
clinical trial data, and time to it takes for the technology to be in 
the hands of the patient? If so, how (and with what catalyst for 
innovation and policy changes) would you advise the VPOTUS for the 
Cancer Moonshot?

Resources

    The USTPO has released a curated data set consisting of 269,353 
patent documents (published patent applications and granted patents) 
spanning the 1976 to 2016 period. This data and associated 
documentation explaining our methodology can be found on the USPTO 
Developer Hub.

Prizes

First Place: $5,000.00
Second Place: $3,000.00
Third Place: $2,000.00

More Information About the Cancer Moonshot Initiative

    As the President's Cancer Moonshot Initiative looks to build 
public-private partnerships with industry, governments, health systems, 
non-profits, philanthropy, research institutes, patients, and academia, 
those interested in advancing the Cancer Moonshot can join today by 
visiting www.whitehouse.gov/CancerMoonshot.

II. Judging Criteria

 Creativity & Innovation (20%)
    [cir] Uniqueness and innovation in approach to revealing new 
insights to guide public policy and research.
    [cir] Concept should be original, fill a gap, or answer a question 
in a manner that is not already available.
 Evidence Base & Effectiveness (20%)
    [cir] Provide meaningful insight, including potential actions and 
discoveries, using patent-related data to better inform funding and 
policy decisions or uncover insights into the cancer R&D process.
    [cir] How did you arrive at and validate your story? Did you 
include additional complimentary datasets to help solidify your story? 
What additional knowledge sources did you use?
 Value to Public (20%)
    [cir] Concept should add value to the medical, research, or data 
communities and policymakers, allowing them to make more informed 
funding and policy decisions based on the patterns and trends of 
innovation in cancer diagnosis and treatment.
 Usability (20%)
    [cir] The design elements should attract, engage, and influence 
actions from the public and policymakers.
 Functional Product (20%)
    [cir] The visualization should have demonstrable functionality as 
described in project description.

III. How To Enter

    By September 12, 2016, 5:00 p.m. Eastern Standard Time, submit the 
following items through www.challenge.gov:
     A story (maximum 1,000 words). Written in English, tell 
the story of your visualization and walk users through how to use your 
visualization. The document must describe how your visualization 
provides meaningful insight, including potential actions and/or 
discoveries.
     Access to and testing instructions for your submission. 
This can be appended to your visualization description and does not 
count toward the 1,000 word maximum.
     Link to the submission. We will not accept any submission 
without a link.

IV. Rules

    To be eligible to win a prize under this challenge, an individual 
or entity:
    (1) Shall have registered to participate in the competition under 
the rules promulgated by the USPTO.
    (2) Shall have complied with all the requirements under this 
section.
    (3) In the case of a private entity, shall be incorporated in and 
maintain a primary place of business in the United States; in the case 
of an individual, whether participating singly or in a group, shall be 
a citizen or permanent resident of the United States.
    (4) Shall not be a federal entity or federal employee acting within 
the scope of their employment.
    (5) Shall not be a USPTO employee working on their applications or 
submissions during assigned duty hours.
    (6) In the case of a federal grantee, shall not use federal funds 
to develop applications unless consistent with the purpose of their 
grant award.
    (7) In the case of a federal contractor, shall not use federal 
funds from a contract to develop applications or to fund efforts in 
support of a challenge submission.
    An individual or entity shall not be deemed ineligible because the 
individual or entity used federal facilities or consulted with federal 
employees during a competition if the facilities and employees are made 
equitably available to all individuals and entities participating in 
the competition.
    Entrants must agree to assume any and all risks and waive claims 
against the Federal Government and its related entities, except in the 
case of willful misconduct, for any injury, death, damage, or loss of 
property, revenue, or profits, whether direct, indirect, or 
consequential, arising from their participation in this prize contest, 
whether the injury, death, damage, or loss arises through negligence or 
otherwise.
    Entrants must also agree to indemnify the Federal Government 
against third-party claims for damages arising from or related to 
competition activities. By entering into this competition, entrants 
represent that the they possess liability insurance or are otherwise 
financially responsible for: (1) Claims by a third party for death, 
bodily injury, or property damage, or loss resulting from an activity 
carried out in connection with participation in the competition, with 
the Federal Government named as an additional insured under the 
Entrant's insurance policy, if any; and (2) claims by the Federal 
Government for damage or loss to government property resulting from 
such an activity.

[[Page 61198]]

    By submitting an entry to this competition you represent and 
warrant that your submission:

 Is your own work and not copied (if we have reason to believe 
that your submission is not your own work then we may not consider it);
 does not contain any third party intellectual property rights 
and/or content that you do not have permission to use; and
 is not obscene, defamatory, or in breach of any applicable 
legislation or regulations.

    The USPTO reserves the right to cancel, suspend, and/or modify the 
challenge, or any part of it, for any reason, at the USPTO's sole 
discretion.

Submission Requirements

     Your submission must use at least the cancer research 
dataset provided by the USPTO.
     Your submission must be relevant to a U.S. audience and 
must be in the English language only.
     You are responsible for the cost and expense (if any) of 
sending your submission to us and, if your submission is selected, 
either attending an awards event demo at the USPTO on September 26, 
2016, in person or submitting a video of your presentation to be shared 
at the event.
     Only one project submission is permitted per person or 
group. In the event of a dispute over the identity of an entrant, the 
submission will be deemed submitted by the authorized account holder of 
the email address submitted during the registration process.
    Submissions that do not adhere to the requirements listed above 
will be automatically disqualified.

Intellectual Property

    Ownership of intellectual property is determined by the following:
     Each entrant retains title and full ownership in and to 
their submission. Entrants expressly reserve all intellectual property 
rights not expressly granted under the challenge agreement.
     By participating in the challenge, each entrant hereby 
irrevocably grants to sponsor and administrator a limited, non-
exclusive, royalty-free, worldwide license and right to reproduce, 
publicly perform, publicly display, and use the submission to the 
extent necessary to administer the challenge, and to publicly perform 
and publicly display the submission, including, without limitation, for 
advertising and promotional purposes relating to the challenge.
     All entrants are encouraged to open source their code to 
the extent possible as a continuing contribution to cancer research.

    Dated: August 31, 2016.
Michelle K. Lee,
Under Secretary of Commerce for Intellectual Property and Director of 
the United States Patent and Trademark Office.
[FR Doc. 2016-21349 Filed 9-2-16; 8:45 am]
 BILLING CODE 3510-16-P